Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    Unilateral unique Lupus tumidus: pathogenetic mystery and diagnostic problem.

    Wien Med Wochenschr 2016 May 13;166(7-8):250-3. Epub 2016 Jan 13.
    Policlinic for Dermatology and Venereology, University Hospital Lozenetz, Koziak street 1, 1407, Sofia, Bulgaria.
    Lupus tumidus is a rare immunological disorder whose pathogenesis is not fully understood. Although on the one hand there are some differences in (1) the clinical morphology of lesions, (2) the histopathology picture, as well as in (3) serological profile of lupus tumidus patients at the current moment, the disease is regarded as a subform of chronic cutaneous lupus erythematosus. Differential diagnosis requires the exclusion of many diseases such as Jessner Kanoff lymphocytic infiltration, polymorphous light eruption, and reticular erythematous mucinosis. Differentiation between them is not always easy. The standard treatment regimen of patients with lupus tumidus is based on local and systemic application of corticosteroids, azathioprin, dapsone, mepacrine, chloroquine, and hydroxychloroquine. Modern treatment options include the use of pulsed dye laser, tacrolimus 0.1 % ointment and photophoresis. We present a 42-year-old patient with unilateral atypical form of lupus tumidus who was successfully treated with systematically administration of hydroxychloroquine in combination with sunscreen SPF 50. After a 2-month course of treatment with hydroxychloroquine dosage of 200 mg per day and a break of 3 months between courses, we observed a complete remission.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with
    Source Status ListingPossible

    Similar Publications

    [Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythematosus].
    Hautarzt 2000 Feb;51(2):82-5
    Hautklinik, Heinrich-Heine-Universität Düsseldorf.
    Antimalarials represent the first line in treatment of cutaneous lupus erythematosus (LE). However, some patients show no improvement on monotherapy with chloroquine or hydroxychloroquine. A 30-year-old female patient had treatment-resistant cutaneous LE exhibiting features of both LE tumidus and subacute cutaneous LE. Read More
    Cutaneous lupus erythematosus. Recognition of its many forms.
    Postgrad Med 1986 Apr;79(5):195-203
    The three major forms of cutaneous lupus erythematosus (LE) are chronic (discoid), subacute, and acute (found in systemic LE). Neonatal LE has recently been recognized as a separate disease with unique therapeutic problems. Subsets of DLE, such as rosaceous DLE, LE panniculitis, verrucous DLE, and chilblain LE, have still different characteristics and prognoses. Read More
    Lupus erythematosus tumidus with discoid lupus erythematosus-induced alopecia of the scalp.
    Dermatol Online J 2011 Oct 15;17(10):24. Epub 2011 Oct 15.
    Department of Dermatology, New York University, New York, New York, USA.
    Lupus erythematosus tumidus (LET) is an uncommon variant of cutaneous lupus erythematosus. Lupus erythematodes tumidus is characterized by smooth, erythematous plaques on sun-exposed areas without surface changes, such as follicular plugs, atrophy, or scale. Histopathologic features include a lymphocytic, perivascular and periadnexal infiltrate with abundant interstitial, superficial, and deep dermal mucin without appreciable epidermal and vacuolar changes. Read More
    [Classification of dermatologic manifestations in lupus erythematosus].
    Ann Med Interne (Paris) 2003 Feb;154(1):33-44
    Service de Médecine Interne, Hôpital de la Pitié, 83, boulevard de l'Hôpital, 75651 Paris Cedex 13.
    Various dermatologic manifestations are observed in the different lupus subsets. Lupus lesions are characterized by a dermo-epidermal dermatitis. Other lesions, vascular or non vascular, are essentially present in association with systemic lupus erythematosus. Read More